stockrowMonte Rosa Therapeutics, Inc.
GLUE Healthcare Biotechnology
Monte Rosa Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $123.7 million, up 63.5% from fiscal 2024.
- Revenue
- +325.8%
- EPS
- +109.1%
- Free cash flow
- −142.6%
Quarter to September 2026, against a year earlier
Follow GLUE
Alert me
Monte Rosa Therapeutics, Inc. (GLUE) EV/Sales
As of 6 November 2026, Monte Rosa Therapeutics, Inc. (GLUE) trades at a EV/Sales of 7.0×. Over the past ten years it has ranged from −0.1× (May 2025) to 65.1× (July 2026); the current reading is higher than 85% of that period. That is below the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 7.5× | 301.95% |
| FY2024 | 1.9× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 9.1× | (85.82%) |
| Jun 2026 | 63.9× | 180.82% |
| Mar 2026 | 22.7× | 203.92% |
| Dec 2025 | 7.5× | 519.41% |
| 7 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LTGO Latigo Biotherapeutics Inc compare | n/m |
| ANRO Alto Neuroscience, Inc. compare | n/m |
| ORIC Oric Pharmaceuticals, Inc. compare | n/m |
| JBIO Jade Biosciences, Inc. compare | n/m |
| IVA Inventiva S.A. Sponsored ADR compare | 1.5× |
| PHAR Pharming Group N.V. Sponsored ADR compare | 2.0× |
| RIGL Rigel Pharmaceuticals, Inc. compare | 2.3× |
| GLUE Monte Rosa Therapeutics, Inc. | 7.0× |
| CTY City Therapeutics, Inc compare | — |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)